Latest News about BMY
Recent news which mentions BMY
5 Stocks Warren Buffett Just Sold From Berkshire's Portfolio
Today 6:37 EST
From Motley Fool
From Benzinga
From Benzinga
Cramer Advises Viewers On Palo Alto, Pfizer, Zillow And More
March 03, 2021
From Benzinga
7 Value Stocks Ready for the Next 10 Years
March 01, 2021
From InvestorPlace
3 Top Stocks That'll Make You Richer in March (and Beyond)
March 01, 2021
From Motley Fool
From Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
February 28, 2021
From Benzinga
Retail, Tech Earnings, and Berkshire's Surprising Buys
February 27, 2021
From Motley Fool
European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
February 26, 2021
From Benzinga
Buy This Blue Chip on the Dip
February 26, 2021
From Motley Fool
Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies
February 25, 2021
From Benzinga
Here's Why Bristol Myers Squibb Is Making A Mistake With Its Cash
February 24, 2021
Tickers
BMY
From Motley Fool
How to Invest Like Warren Buffett in 2021
February 24, 2021
From Motley Fool
Bristol Myers Is Taking Full Advantage of its Celgene Acquisition
February 24, 2021
Tickers
BMY
From Motley Fool
Warren Buffett Just Bought These 2 Dirt-Cheap Stocks. Should You?
February 23, 2021
From Motley Fool
Compugen To Test COM701, Opdivo Combination In Solid Tumor Settings
February 22, 2021
From Benzinga
Your 2 Best Profit Opportunities in 2021
February 20, 2021
From Motley Fool
From Benzinga
3 High-Quality Health Care Companies With Recession-Proof Dividends
February 19, 2021
From InvestorPlace
Own Big Stock Winners? Handle Them the Warren Buffett Way
February 19, 2021
From Motley Fool
Here Are All 10 Stocks Warren Buffett Has Been Buying
February 18, 2021
From Motley Fool
Warren Buffett's Berkshire Cuts Apple Stake And Buys These Drugmaker, Telecom Stocks Instead
February 16, 2021
From Benzinga
Bristol-Myers, Sanofi Fined $834M In Hawaii Over Plavix: Bloomberg
February 16, 2021
From Benzinga
From Benzinga
Exelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor Settings
February 16, 2021
From Benzinga
Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer
February 16, 2021
From Benzinga
Why Illumina Stock Is Skyrocketing Today
February 12, 2021
From Motley Fool
Why Infinity Pharmaceuticals Is Skyrocketing Today
February 11, 2021
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.